AXIM Biotechnologies, Inc.
AXIM
Rank in Stocks
#32867
AXIM Biotechnologies, Inc. specializes in the creation and distribution of... AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Share Price
$0.003
Last synced: 2026-11-11
Market Cap
$1.05M
Change (1 day)
-6.25%
Change (1 year)
-77.31%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AXIM Biotechnologies, Inc. (AXIM)
Category
Healthcare
EPS for AXIM Biotechnologies, Inc. (AXIM)
EPS as of June 2026 TTM: $0.00
According to AXIM Biotechnologies, Inc.'s latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-0.01.
EPS history for AXIM Biotechnologies, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -71.82% |
| 2025 | 0.00 | -71.82% |
| 2024 | $-0.01 | -68.93% |
| 2023 | $-0.04 | -1.67% |
| 2022 | $-0.04 | -72.31% |
| 2021 | $-0.13 | 113.11% |
| 2020 | $-0.06 | -44.55% |
| 2019 | $-0.11 | -8.33% |
| 2018 | $-0.12 | 53.45% |
| 2017 | $-0.08 | -44.14% |
| 2016 | $-0.14 | -48.15% |
| 2015 | $-0.27 | 1,425.42% |
| 2014 | $-0.02 | 555.56% |
| 2013 | 0.00 | 440.00% |
| 2012 | 0.00 | 400.00% |
| 2011 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 46,742.11% |
US
|
|
| $15.66 | -824,310.53% |
US
|
|
| $-7.07 | 372,005.26% |
US
|
|
| $-5.29 | 278,321.05% |
AU
|
|
| $12.73 | -670,215.79% |
BE
|
Questions about AXIM Biotechnologies, Inc.'s earnings per share (EPS)
What is AXIM Biotechnologies, Inc.'s earnings per share (EPS)?
AXIM Biotechnologies, Inc.'s earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was AXIM Biotechnologies, Inc.'s earnings per share (EPS) in 2025?
In 2025, AXIM Biotechnologies, Inc.'s earnings per share (EPS) was 0.00, compared with $-0.01 in 2024.
How has AXIM Biotechnologies, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, AXIM Biotechnologies, Inc.'s earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2021 ($-0.13).
How does AXIM Biotechnologies, Inc.'s earnings per share (EPS) compare with similar companies?
AXIM Biotechnologies, Inc.'s earnings per share (EPS) ($0.00) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.